Your new experience awaits. Try the new design now and help us make it even better

REVIEW article

Front. Cardiovasc. Med.

Sec. Cardiovascular Epidemiology and Prevention

This article is part of the Research TopicEnvironmental Determinants of Cardiovascular Health: Interactions with Lifestyle and Socioeconomic FactorsView all 13 articles

Preventing Premature Cardiovascular Mortality: The Role of Lifestyle Interventions and Pharmacotherapy - A Narrative Review

Provisionally accepted
  • 1American University of Beirut, Beirut, Lebanon
  • 2Lebanese American University, Beirut, Lebanon
  • 3University of Balamand, Balamand, Lebanon

The final, formatted version of the article will be published soon.

Cardiovascular diseases (CVD), including coronary heart disease, cerebrovascular disease, and peripheral artery diseases, are the leading global cause of premature mortality in adults. Addressing CVD aligns with the United Nations Sustainable Development Goals aiming to reduce premature deaths by one-third by 2030 through lifestyle and pharmacological interventions. Major risk factors for CVD are categorized into lifestyle and genetic factors. Lifestyle factors such as elevated cholesterol, hypertension, high body mass index, smoking, poor dietary habits, and physical inactivity significantly increase CVD mortality. Conversely, genetic predisposition strongly influences individual risk, often amplified by unhealthy behaviors. Primary prevention strategies, including adherence to Dietary Approaches to Stop Hypertension (DASH) and Mediterranean Diet (MD), regular physical activity, and smoking cessation, have demonstrated effectiveness in reducing CVD incidence and mortality. Secondary prevention emphasizes pharmacological interventions, specifically aspirin and statin therapies, non-statin agents, antihypertensive, all of which significantly decrease recurrent cardiovascular events among high-risk individuals. Although cardiovascular screening practices remain debated, targeted screening informed by precision medicine approaches and artificial intelligence shows promise in stratifying risk effectively. This review synthesizes evidence on these preventive strategies, underscoring their integrated role in reducing premature CVD-related mortality, while recognizing the need for further implementation research to optimize preventive healthcare outcomes.

Keywords: Cardiovascular disease prevention, premature mortality, lifestyle interventions, Pharmacotherapy, risk stratification

Received: 12 Jul 2025; Accepted: 25 Nov 2025.

Copyright: © 2025 Haber, Nasr, El Etry and Nasr. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Marc Haber

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.